Executive Chairman & Director
Philip Astley-Sparke is Executive Chairman and co-founder of Replimune. Previously he was the President and CEO of BioVex Inc where he also acted as the company’s Chairman from November 2009 until March 2011, when the company was acquired by Amgen for up to $1bn ($425m up-front). Subsequent to BioVex/Amgen, Philip was President at Uniqure where he led a $92m NASDAQ IPO and established their US infrastructure including the world’s largest gene therapy manufacturing facility. Philip is currently Chairman at Oxyrane, a Venture Partner at Forbion Capital and a board member for Uniqure. Philip received a BSc in Cellular and Molecular Pathology from Bristol University UK, qualified as a Chartered Accountant with Arthur Andersen and was a healthcare investment banker with Robert Fleming / Chase H&Q prior to joining BioVex.
CEO & Director
Robert Coffin is co-founder and CEO of Replimune. Previously he was Founder & CTO of BioVex Inc, a spin out from his research group at University College London in 1999. Rob was the inventor of all BioVex products including OncoVEXGM-CSF (talimogene laherparepvec; T-VEC; Imlygic) and oversaw all research and clinical development including bringing T-VEC through to two pivotal phase 3 studies in melanoma and head & neck cancer. BioVex was acquired by Amgen in 2011 where Rob was VP Global Development until 2013. T-VEC was approved by the FDA for use in advanced melanoma in October 2015, the first oncolytic therapy or gene therapy to be approved in the US. Rob was awarded a PhD in virology from Imperial College London prior to his move to University College London in 1991.
Jason Rhodes is a partner with Atlas Venture and focuses on the creation, development and business strategy of novel therapeutics companies. Prior to Atlas, Jason was President and Chief Financial Officer of Epizyme, Inc. (NASDAQ: EPZM). Jason joined Epizyme when it was a private, venture-backed company and was instrumental in charting the company’s strategic course and building the business, leading to Epizyme’s successful IPO in 2013. He established and was responsible for all business functions and led the company’s partnerships with Celgene, GSK, and Eisai. Prior to Epizyme, Jason was Vice President of Business Development at Alnylam (NASDAQ: ALNY), where he led partnerships with company’s including Takeda, GSK, Isis, Cubist, Kyowa Hakko Kirin, and Medtronic and the spin out of Regulus Therapeutics (NASDAQ: RGLS). Prior to Alnylam, Jason was a founder and partner with Fidelity Biosciences, the life sciences venture capital arm of Fidelity Investments, where he led investments in therapeutics companies including Ironwood Pharmaceuticals (NASDAQ: IRWD), FoldRx (purchased by Pfizer), and Tetraphase (NASDAQ: TTPH). Jason received his BA from Yale University and his MBA from the Wharton School of the University of Pennsylvania.
Sander is Managing Partner of Forbion Capital Partners and co-founded ABN AMRO Capital Life Sciences in 2000 and Forbion Capital Partners in 2006. He currently serves on the boards of Forbion’s portfolio companies Xention Discovery Ltd, Ario Pharma Ltd, Pulmagen Therapeutics, Ltd and Oxyrane Ltd. In addition, Sander was responsible for two of Forbion’s more recent exits: Dezima Pharma B.V. was sold to Amgen in September of 2015 for up to USD 1.55 billion plus royalties and Biovex, Inc. was sold to Amgen in March of 2011 for up to USD 1 billion. In recent years Sander has served on the boards of uniQure N.V. (QURE), Fovea Pharmaceutics S.A.(Sold to Sanofi in 2009), Argenta Discovery Ltd (sold to Galapagos in 2010), Alantos Pharmaceuticals, Inc. (sold to Amgen in 2007), Impella Cardiosystems AG (sold to Abiomed, Inc. in 2005), Glycart AG (sold to Roche in 2005), Cambridge Drug Discovery Ltd (sold to Biofocus Plc in 2001), Pieris AG (PIRS) and has acted as the Chairman of the Board of AMT NV (Amsterdam, Netherlands / Euronext: AMT). Before co-founding Forbion Capital Partners, he was an Investment Director at ABN AMRO Capital Life Sciences. His other activities at ABN AMRO included buy-out/ growth equities at ABN AMRO Capital, Equity Capital Markets Syndications (HQ Amsterdam) and Financial Institutions Relationship Management Latin America (Regional Office Miami). Sander holds degrees in Business and Financial Economics from the Free University of Amsterdam and Business Administration from Nijenrode University, The Netherlands.
Otello Stampacchia is a partner at Omega Funds where he has had particular recent involvement in investments in Micromet, BioVex, Juno and Jounce Therapeutics. Previously, Otello was in charge of life sciences direct investments at AlpInvest Partners, one of the largest private equity asset managers worldwide. At AlpInvest, Otello was responsible for the direct life sciences investments, as well as assisting in due diligence for healthcare venture fund of funds investments. Before AlpInvest, Otello was the portfolio manager of the Lombard Odier Immunology Fund, a $3bn listed investment vehicle, investing in public and private healthcare companies worldwide. Previously, Otello was a member of the HealthCare corporate finance and M&A team at Goldman Sachs. Before joining Goldman, Otello helped co-found the healthcare investment activities at Index Securities (now Index Ventures). Otello has a PhD in Molecular Biology from the University of Geneva (Switzerland), and a PhD in Biotechnology.
From 1999 to 2008 Dr. Kapil Dhingra served at Hoffmann-La Roche, including as Vice President, Head, Oncology Disease Biology Leadership Team, and Head, Oncology Clinical Development. Prior to joining Roche, he worked in the oncology clinical development group at Eli Lilly and Company. From 1989 to 1996, he was a faculty member at The University of Texas M.D. Anderson Cancer Center and during his industry career maintained active faculty appointments at Indiana University School of Medicine from 1997 to 1999, and at Memorial Sloan Kettering Cancer Center in New York from 2000 to 2008. Kapil is board-certified in Internal Medicine and Medical Oncology and is currently Chairman of Board of Exosome Diagnostics and member of Boards of Directors of Advanced Accelerator Applications, Five Prime, and Autolus. He is also a member of the NCI Experimental Therapeutics panel and a member of the New Drug Advisory Committee of the EORTC. He has previously served on the Boards of several successful biotech companies, including Biovex, Micromet, Algeta, YM Biosciences, and Epitherapeutics which were all acquired by major pharmaceutical companies. Kapil founded KAPital Consulting, LLC, in 2008, a company dedicated to helping biotechnology, pharmaceutical and diagnostic companies realize the clinical and commercial advances in oncology.